Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea
FLPOD24
1 other identifier
observational
80
1 country
1
Brief Summary
This retrospective study was proposed by the investigators to analyze treatment status and outcome in patients with early relapsed follicular lymphoma. In patients with follicular lymphoma who experienced disease progression within 24 months after initiation of treatment, the second-line therapy, stem cell transplantation, tumor response, progression free survival, and overall survival will be analyzed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 8, 2019
CompletedFirst Submitted
Initial submission to the registry
August 2, 2019
CompletedFirst Posted
Study publicly available on registry
August 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2020
CompletedAugust 7, 2019
August 1, 2019
10 months
August 2, 2019
August 5, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival
Overall survival is defined as the time from the diagnosis to death or last follow-up.
from the date of the IRB approval until 12 month
Secondary Outcomes (1)
Progression free survival
from the date of the IRB approval until 12 month
Study Arms (1)
Follicular lymphoma arm
The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
Eligibility Criteria
The analysis will involve patients diagnosed with follicular lymphoma who received induction chemotherapy and then experienced a worsening of disease within 24 months from the start date of the treatment.
You may qualify if:
- Patients histologically diagnosed with follicular lymphoma (ICD-10 C82.0 to C82.9)
- Radiologically confirmed disease progression within 24 months from the start date of an induction chemotherapy
- All of the following should be available for retrospective analysis.
- Pathologic findings report
- Medical records containing age, sex, date of diagnosis, clinical symptoms, laboratory findings, treatment methods, progression, survival, death, etc.
You may not qualify if:
- Known histologic transformation to aggressive lymphoma
- Follicular lymphoma grade 3B
- Patients whose pathologic findings report and appropriate medical records are not available
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, 06351, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wonseog Kim, Professor
Samsung Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 2, 2019
First Posted
August 7, 2019
Study Start
July 8, 2019
Primary Completion
April 30, 2020
Study Completion
April 30, 2020
Last Updated
August 7, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share